400 Wood Road
United States - Map
Haemonetics Corporation is engaged in the design, development, manufacture, and marketing of automated blood component collection devices and surgical blood salvage devices in the United States and internationally. It provides various plasma products, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and blood center products comprising multicomponent collection system brand apheresis equipment to collect specific blood components integrated from the donor, automated cell processor brand solution to automate the washing and freezing of red cell components in the lab, and filtration products. The company also offers various hospital products, such as TEG thrombelastograph hemostasis analyzer system that measures a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system for cardiovascular surgery procedures; OrthoPAT surgical blood salvage system for orthopedic procedures; and IMPACT Online Web-based software platform that monitors and measures improvements in a hospitals blood management practices. In addition, it offers SafeTrace Tx and BloodTrack suite of solutions, as well as El Dorado Donor donation and blood unit management systems. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
|Haemonetics Corporation’s ISS Governance QuickScore as of Oct 1, 2014 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 7; Compensation: 3.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Brian P. Concannon ,
Chief Exec. Officer, Pres and Director
|Mr. Christopher J. Lindop ,
Chief Financial Officer and Exec. VP of Bus. Devel.
|Dr. Jonathan White ,
Chief Science & Technology Officer
|Mr. Peter M. Allen ,
Pres of Global Plasma
|Ms. Susan M. Hanlon ,
Chief Accounting Officer and VP of Fin.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|